Baxter International Inc (BAX) : Towerview has sold out all of its stake in Baxter International Inc during the most recent quarter, according to the disclosure filed by the company on Jul 20, 2016 with the SEC. The investment management company has sold out 40,000 shares of Baxter International Inc which is valued at $1,852,800.
Other Hedge Funds, Including , Wealthtrust-arizona reduced its stake in BAX by selling 99 shares or 32.78% in the most recent quarter. The Hedge Fund company now holds 203 shares of BAX which is valued at $9,403. Baxter International Inc makes up approx 0.01% of Wealthtrust-arizona’s portfolio.Hexavest reduced its stake in BAX by selling 443 shares or 5.27% in the most recent quarter. The Hedge Fund company now holds 7,964 shares of BAX which is valued at $370,724. Baxter International Inc makes up approx 0.01% of Hexavest’s portfolio.Capital Analysts reduced its stake in BAX by selling 90 shares or 14.63% in the most recent quarter. The Hedge Fund company now holds 525 shares of BAX which is valued at $24,439. Mutual Of Omaha Bank Wealth Management added BAX to its portfolio by purchasing 4,000 company shares during the most recent quarter which is valued at $187,280. Baxter International Inc makes up approx 0.06% of Mutual Of Omaha Bank Wealth Management’s portfolio.Benjamin F. Edwards Company reduced its stake in BAX by selling 361 shares or 13.11% in the most recent quarter. The Hedge Fund company now holds 2,393 shares of BAX which is valued at $112,040. Baxter International Inc makes up approx 0.02% of Benjamin F. Edwards Company’s portfolio.
Baxter International Inc opened for trading at $46.48 and hit $46.86 on the upside on Wednesday, eventually ending the session at $46.7, with a gain of 1.08% or 0.5 points. The heightened volatility saw the trading volume jump to 16,63,151 shares. Company has a market cap of $25,791 M.
On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.
Investors should note that on Jul 19, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Aug 31, 2016 as the ex-dividend date and fixed the record date on Sep 2, 2016. The payable date has been fixed on Oct 3, 2016.
Many Wall Street Analysts have commented on Baxter International Inc. Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.